Myoridge is Drug Discovery in Japan that focus on regenerative medicine business. Founded in 2016. They cover business area such as operator, cell-derive cardiomyocyte, a protein-free medium, low production cost, no protein, lot, human cardiomyocyte, researcher, new breakthrough, regenerative medicine and drug development technology.
2016
( 10 years old in 2026 )
Regenerative Medicine
-
Room 305, Med-Pharm Collaboration Building
Kyoto University, 46-29 Yoshidashimoadachi, Sakyo-ku
Kyoto, 606-8501
Japan
Private
operatorcell-derive cardiomyocytea protein-free mediumlow production costno proteinlothuman cardiomyocyteresearchernew breakthroughregenerative medicine and drug development technology
* We use standard office opening hours in near Myoridge's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Myoridge is Drug Discovery business from Japan that founded in 2016 (10 years old in 2026), Myoridge business is focusing on Regenerative Medicine.
Myoridge headquarter office and corporate office address is located in Room 305, Med-Pharm Collaboration Building Kyoto University, 46-29 Yoshidashimoadachi, Sakyo-ku Kyoto, 606-8501 Japan.
Myoridge was founded in Japan.
In 2026, Myoridge is currently focus on regenerative medicine sector.
Above is snippet of Google Trends for "regenerative medicine" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Myoridge, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
